Lina Khan Is Sending a Message to the Private Equity Industry

This podcast episode explores the Federal Trade Commission's (FTC) recent actions under Chair Lina Khan, focusing on the agency's antitrust enforcement efforts in the healthcare industry, particularly regarding private equity firms' involvement, non-compete clauses, and drug pricing. Khan emphasizes the need for robust competition to address healthcare costs and quality issues. Takeaways • The FTC is aggressively pursuing antitrust enforcement, particularly in industries with consolidation and limited competition, such as healthcare. • Private equity firms' roll-up strategies in the healthcare sector are under scrutiny for potentially harming competition and raising prices. • The FTC has proposed a rule to eliminate non-compete clauses in employment contracts for most workers, given their negative impact on worker mobility and competition. • Antitrust laws encompass the protection of workers and fair competition, as seen in cases involving student athletes, publishers, and non-compete clauses during the pandemic. • The current antitrust approach needs reform, as evidenced by rising monopoly power and market failures. • The FTC's recent enforcement actions against anticompetitive practices in the pharmaceutical industry have had a deterrent effect. • The podcast highlights the need to address monopsony power, protect doctors from unfair practices, and examine the role of corporate practice of medicine in future episodes.